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Epigenetic analysis shows that many genes that suppress malignancy are silenced by
aberrant DNA methylation in lung cancer. Many of these genes are interesting targets for
reactivation by the inhibitor of DNA methylation, decitabine (5-aza-2′-deoxycytidine, DAC). A
pilot study on intense dose DAC showed promising results in patients with metastatic non-
small cell lung cancer (NSCLC). However, subsequent clinical studies using low dose DAC
were not very effective against NSCLC and interest in this therapy diminished. Recently,
interesting responses were observed in a patient with NSCLC following treatment with a
combination of the related inhibitor of DNA methylation, 5-azacytidine, and an inhibitor of
histone deacetylation.This finding has generated a renewed interest in the epigenetic ther-
apy of lung cancer. Preclinical studies indicate that DAC has remarkable chemotherapeutic
potential for tumor therapy. This epigenetic agent has a delayed and prolonged epigenetic
action on tumor cells. This delayed action should be taken into consideration in the design
and evaluation of clinical studies on DAC. Future research should be directed at finding the
optimal dose-schedule of de DAC for the treatment of NSCLC.
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INTRODUCTION
The life expectancy of most patients with metastatic non-small cell
lung cancer (NSCLC) following standard chemotherapy is very
limited (1–3). There is an urgent need to develop more effec-
tive treatments for this malignancy. Molecular changes that place
in the genome of lung cancer cells can give insight to novel tar-
gets for chemotherapeutic intervention. Analysis of the genome
of lung cancer shows that both genetic and epigenetic events
are implicated in tumorigenesis. It is not possible to reverse the
genetic aberrations with current chemotherapy. However, epige-
netic changes are reversible and interesting targets for chemother-
apeutic intervention. One of the major epigenetic changes that
take place in lung cancer is aberrant DNA methylation in the pro-
moter region of genes that suppress malignancy. The silencing of
these genes can promote tumorigenesis by several mechanisms
including increasing cell proliferation, inactivation of genes that
suppress metastasis and angiogenesis, suppressing apoptosis, and
DNA repair. These genes are interesting targets for intervention
using a potent inhibitor of DNA methylation, such a decitabine
(5-aza-2′-deoxycytidine, DAC).
PHARMACOLOGY OF DECITABINE
5-Aza-2′-deoxycytidine is an analog of deoxycytidine and a pro-
drug that has to be activated by photophosphorylation by deoxy-
cytidine kinase (4). Since its antineoplastic action is dependent
on its incorporation into DNA, DAC is an S phase specific agent.
The incorporation of DAC in place of 5-methylcytosine in DNA
results in the inactivation of DNA methyltransferase 1 due to cova-
lent bond formation between the 5-azacytosine ring of DAC and
this enzyme. The end result of this process is hypomethylation of
DNA. Genes that are silenced by aberrant DNA methylation can
be reactivated by treatment with DAC. Both leukemic and tumor
cells are very sensitive to the antineoplastic action of low concen-
trations of DAC. In animal models of leukemia and cancer, DAC
shows curative potential (5). The antineoplastic action of DAC is
very dose-schedule dependent. The major side effect of DAC is
granulocytopenia.
PILOT STUDY ON DAC IN PATIENTS WITH ADVANCED NSCLC
A phase I–II clinical trial on DAC was performed at our Univer-
sity medical center on patients with stage IV NSCLC who had
received no prior chemotherapy (6). The patients received an 8-h
i.v. Infusion of DAC at intense doses of 200–660 mg/m2. For five
patients that received 2–4 cycles of DAC, three patients survived
4.3–9.3 months, and two patients survived 15.3 and 16 months,
respectively. (7). One patient that received five cycles of DAC
survived 81 months. This latter patient was removed from the
DAC study due to tumor progression and was treated with three
cycles of vindesine over 15 month interval. She then received no
further chemotherapy and eventually expired due to tumor pro-
gression. Due to the lack of understanding of the delayed action
of DAC some patients were removed from the clinical study due
to signs of tumor progression. The estimated steady state plasma
concentration of DAC during the infusion of 660 mg/m2 in this
patient was 2.6µM. Due to the small sample size many oncolo-
gists may consider these interesting responses with intense dose
DAC in patients with NSCLC as only anecdotal. This conclusion
is supported by clinical trial using low dose DAC in patients with
advanced NSCLC (8). Sixteen patients with stage IV NSCLC, ade-
nocarcinoma diagnosis, were administered DAC as 72-h infusion
at doses of 60–90 mg/m2 total. Most patients received two cycles
of DAC. The overall response for all the patients was progressive
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disease. The estimated plasma concentration of DAC for these
patients was in the range of 0.04–0.06µM, which is 40- to 60-fold
lower than observed with intense dose DAC.
ANALYSIS OF STUDY ON INTENSE DOSE DAC IN PATIENTS
WITH NSCLC
The key question with respect to intense dose DAC for the treat-
ment of NSCLC is the observed responses an indication of its
chemotherapeutic potential or just chance occurrence that rarely
takes place. It is essential to look at both the clinical and preclin-
ical data on an experimental drug before making a decision to
continue or abandon future clinical investigations. An example of
how this process can take place is described below on different key
parameters that should be taken into account. One key mistake
that should be avoided is to conclude that an experimental drug
does not merit additional investigation based on the data from a
clinical trial that used a very poor and suboptimal dose-schedule
for the drug.
MOLECULAR MECHANISM OF ACTION
5-Aza-2′-deoxycytidine has a novel mechanism of action of reac-
tivating genes that prevent or suppress malignancy. A list of some
of the target genes is shown in Table 1. It is possible that there are
many other genes that suppress malignancy that are also reacti-
vated by DAC, but still have not been identified. Since DAC has
many gene targets in malignant cells, does it have more therapeu-
tic potential than an agent that targets only a single gene? Future
investigations will answer this question.
THERAPEUTIC CONCENTRATION AND DURATION OF EXPOSURE
The in vitro studies on the antineoplastic activity of DAC on
human lung carcinoma cells provide the data on what concen-
tration and exposure time is required to reduce colony formation.
DAC at 0.44µM for 8 h exposure reduced colony formation of
SK-MES-1 and NCI-H520 lung carcinoma cells by 47.3 and 21.7%,
respectively (6). A 10-fold higher concentration of 4.4µM of DAC
reduced colony formation by 76% for both cell lines. In the mouse
tumor model the infusion of DAC for 18-h to give a steady state
plasma level of 2.9µM produced a 2-log cell kill of the tumor cells
(5). In comparison, the patient who survived>5 years received an
8-h infusion of DAC at a dose of 660 mg/m2, which produced a
plasma level was 2.7µM. This interesting correlation shows that
in the clinical trial with intense dose DAC, concentrations of this
analog were present in the plasma of the patients that had the
potential to significantly reduce the clonogenic potential of the
tumor cells.
DURATION OF TREATMENT
The in vitro colony assay shows that the longer exposure time of
24-h was more effective than the 8-h exposure. DAC at 4.4µM
exposure for 24-h produced a >90% reduction in colony forma-
tion for both the lung carcinoma cell lines (6). In a mouse tumor
model a 24-h infusion of DAC was much more effective than a 6-
or 12-h infusion (9). This shows that the 8-h infusion used in the
clinical study was clearly suboptimal, but was chosen to avoid the
risk of unacceptable toxicity for the first patients that entered the
phase I trial. The preclinical data support the use of longer infusion
times of DAC in future clinical trials in patients with NSCLC.
Table 1 |Tumor suppressor genes silenced by aberrant DNA
methylation in lung cancer.
Gene Function Reference
BHLHB4 Transcriptional regulator, differentiation (23)
BLU Transcription repressor (17, 23)
CDKN2A Inhibitor cyclin-dependent kinase; cell cycle arrest (15, 16)
CDH1 Cell adhesion/metastasis (16)
CDH13 Cell adhesion (16)
CXCL14 Pro-apoptosis, cell cycle arrest (24)
DAPK1 Apoptosis (16)
DKK3 Wnt pathway antagonist (21)
DCL1 Cell growth, apoptosis, cell adhesion (15)
HOXA
genes
Homeobox transcriptions factors; differentiation (22)
MGMT DNA repair (16, 23)
MMP2 Degradation extracellular matrix (23)
RARß Retinoic acid receptor ß; differentiation (16)
RASSF1A Cell cycle control (16, 17, 25)
Reprimo Mediator of p53-mediated cell cycle arrest (20)
RUNX3 Transcription factor target TGF-ßpathway (25)
SFRP1 Antagonist of Wnt pathway (26)
TCF1 Differentiation (19)
TIMP3 Tissue inhibitor of metalloproteinase 3; metastasis (15)
WIF1 Antagonist of WNT pathway (18)
DESIGN OF CLINICAL TRIALS ON DAC IN PATIENTS WITH
NSCLC
It is not justified to conclude that DAC is weak antitumor drug
based on the results of clinical trial that used very poor dose-
schedule? In order to determine the full chemotherapeutic poten-
tial of DAC for the treatment of lung cancer, it is important to
find its optimal dose-schedule. Several suggestions are summa-
rized here for the design of a clinical trial on DAC in patients
with NSCLC with the long-term objective of finding its optimal
dose-schedule for cancer treatment.
PATIENT SELECTION
The major toxicity produced by DAC is myelosuppression. The
patients with NSCL that are candidates for a clinical trial on
intense doses of decitabine should have a good performance and
hematologic status. A minimum of 4 weeks after previous cyto-
toxic chemotherapy is necessary to permit adequate recovery from
bone marrow toxicity. An interesting cohort of NSCLC patients
would be those who were previously treated with targeted agents
(Erlotinib, Gefitinib), which produce no hematotoxicity.
DOSE OF DAC
One of the major reasons for failure of cancer chemotherapy is
the limited penetration of cytotoxic drugs into tumors (10). Due
to the low therapeutic index of most cytotoxic anticancer drugs,
there is a limit that one can increase the dose to obtain therapeutic
concentrations in the central region of the tumor microenviron-
ment. In this regard, the S phase specificity of DAC permits the
use of high doses of this agent for cancer treatment. The scien-
tific rationale for the use of intensive doses of DAC is based on
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its comparative pharmacology to ARA-C. Both these agents are
analogs of deoxycytidine, have an identical metabolism and their
antineoplastic action is due to their incorporation in DNA. How-
ever, their mechanisms of action are different. ARA-C is a potent
inhibitor of DNA replication, whereas DAC is potent inhibitor
of DNA methylation. In clinical trials in patients with leukemia
the standard ARA-C dose of 100 mg/m2/day was increased to
6,000 mg/m2/day (11). This represents a 60-fold increase in the
total dose per day for ARA-C. Since both deoxycytidine analogs
target the same S phase cells, their profiles for hematopoietic tox-
icity are similar. The preclinical data predict that concentrations
of DAC >1µM are required to obtain a potent antitumor effect.
This drug should be infused at a rate that gives this level in the
plasma. For example, an infusion rate of 50 mg/m2/h of DAC
gives a steady state plasma concentration for DAC in the range
of 2µM.
DURATION OF DAC INFUSION
The preclinical data clearly show that a 24-h drug exposure is
much more effective than an 8-h exposure of DAC against human
lung carcinoma cells (6). Without question the conservative 8 h
infusion that was used in our pilot clinical study on lung cancer
was too short to produce good responses in all patients. A good
starting dose-schedule to use for DAC in a clinical trial in patients
with metastatic NSCLC would be 50 mg/m2/h for 18 h for a total
dose of 900 mg/m2. The key objective of this dense dose DAC ther-
apy is to eradicate the proliferative potential of the most rapidly
growing tumor stem cells. Depending on the response and adverse
events, the rate of drug infusion rate can be kept constant and the
duration of the infusion increased by intervals of 6 h.
DURATION BETWEEN CYCLES OF DAC THERAPY
Myelosuppression is the major toxicity produced by DAC. Due
to the delayed epigenetic action of DAC on hematopoietic cells,
the recovery from granulocytopenia takes about 2 weeks longer
than that observed with cytotoxic chemotherapy, such as ARA-C
(12). Many centers used a 4-week interval between cycles of cyto-
toxic chemotherapy. In the case of DAC, it is recommended to
use a 6-week interval between cycles so as to permit a more full
recovery of the granulocyte count. The delayed epigenetic action
of DAC also takes place on the tumor cells, which results in a
slower recovery of their growth potential as compared to cyto-
toxic agents, which also permits a longer interval between cycles
of chemotherapy.
MONITOR OF CLINICAL RESPONSE
Tumor cells treated with DAC undergo several cell divisions before
growth arrest due to the time this epigenetic agent takes to
reactivate the expression of silent tumor suppressor genes. With-
out a sound understanding of the delayed epigenetic action of
DAC, one can conclude that the tumor is resistant to this agent.
An increase in tumor size of ≥20% after drug treatment is an
indication for removal of the patient from the clinical study
at many treatment centers. It is suggested that this criteria for
patient removal from the study should be increased to ≥50% for
DAC. This suggestion should be confirmed by careful evaluation
and may have to be modified depending on long-term clinical
response.
NUMBER OF CYCLES OF DAC TREATMENT
The patient with NSCLC that survived 81 months in our pilot
study received five cycles of DAC (6). It is recommended that
patients with good performance status also be administered five
cycles of intense dose DAC.
CONCLUSION
The epigenetic agent DAC shows considerable promise for the
treatment of NSCLC. The interesting response observed in a
patient with NSCLC following treatment with a combination of
inhibitors of DNA methylation and histone deacetylation is an
indication of that positive results can be obtained with epigenetic
agents (13). This latter study confirms both our preclinical and
clinical studies on DAC (6, 14). A good understanding of the phar-
macology of DAC and its delayed epigenetic action on tumor cells
should be taken into consideration in the design of clinical trials on
patients with advanced NSCLC (4, 9, 12). The full chemotherapeu-
tic potential of epigenetic therapy of cancers will require intensive
clinical investigation (5). Table 1 summarizes the large number
tumor suppressor genes that are silenced by aberrant DNA methy-
lation in NSCLC (15–26) and which are interesting targets for DAC
therapy. These observations provide a positive outlook for future
progress for the therapy of lung cancer.
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